Advertisement
Singapore markets close in 7 hours 9 minutes

  • Straits Times Index

    3,264.27
    -28.86 (-0.88%)
     

  • Nikkei

    37,931.01
    -529.07 (-1.38%)
     

  • Hang Seng

    17,129.26
    -72.01 (-0.42%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,312.77
    -2,550.56 (-3.81%)
     

  • CMC Crypto 200

    1,395.29
    -28.81 (-2.02%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,331.70
    -6.70 (-0.29%)
     

  • Crude Oil

    82.66
    -0.15 (-0.18%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,572.19
    +0.71 (+0.05%)
     

  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     

  • PSE Index

    6,594.13
    +21.38 (+0.33%)
     

AbbVie settles Humira biosimilar dispute with Fresenius Kabi

Reuters
Fresenius headquarters in Bad Homburg near Frankfurt, Germany, February 27, 2018. REUTERS/Ralph Orlowski/File Photo (Reuters)

(Reuters) - U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug.

In the European Union, Fresenius Kabi can launch its biosimilar upon approval from the European Medicines Agency, while the license period in the United States will begin on Sept. 30, 2023, AbbVie said.

Fresenius Kabi will pay royalties to AbbVie for licensing its patents for Humira, which is used to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.

The settlement comes days after rival versions of AbbVie's top-selling drug went on sale in Europe, years ahead of similar cut-price copies being available in the United States.

ADVERTISEMENT

Amgen has rolled out its so-called biosimilar form of Humira, branded as Amgevita, across Europe, while Novartis said its Sandoz unit was launching a copy-cat version, Hyrimoz, initially in Britain, with other markets set to follow.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Maju Samuel)